A cerium oxide-based nanomedicine for pH-triggered chemodynamic/chemo combination therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Chemodynamic therapy (CDT) offers a promising cancer treatment with fewer side effects.
• Combining CDT with chemotherapy can improve efficacy, but may increase side effects.
• Developing targeted combination therapies is crucial for effective cancer treatment.

Purpose of the Study:

• To develop a pH-triggered nanomedicine for combined chemodynamic and chemotherapy.
• To enhance cancer cell internalization and therapeutic efficacy.
• To minimize side effects associated with combination cancer therapies.

Main Methods:

• Fabrication of CeO2-MnO2 nanorods (CMNRs) coated with RGD-conjugated charge-reversal polymers.
• Loading doxorubicin (DOX) onto the modified nanorods to create DOX@PCMNR-RGD.
• Evaluation of pH-triggered charge reversal, cellular uptake, and combined therapeutic activity in vitro.

Main Results:

• The DOX@PCMNR-RGD nanomedicine exhibited pH-triggered charge reversal, enhancing cellular uptake in acidic tumor microenvironments.
• The nanomedicine effectively catalyzed H2O2 into toxic hydroxyl radicals (CDT activity) under acidic conditions.
• Acidic conditions triggered DOX release, demonstrating chemotherapeutic activity, leading to synergistic anti-cancer effects.

Conclusions:

• The developed nanoplatform offers a pH-triggered dual-modal therapeutic strategy for cancer treatment.
• This approach combines the benefits of chemodynamic and chemotherapy with reduced side effects.
• The study presents a novel nanomedicine design for targeted and effective cancer therapy.